HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ana M Bajo Selected Research

Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))

2/2015VIP induces NF-κB1-nuclear localisation through different signalling pathways in human tumour and non-tumour prostate cells.
8/2014Signalling pathways involved in antitumoral effects of VIP in human renal cell carcinoma A498 cells: VIP induction of p53 expression.
8/2013Antitumoral effects of vasoactive intestinal peptide in human renal cell carcinoma xenografts in athymic nude mice.
1/2013Vasoactive intestinal peptide induces oxidative stress and suppresses metastatic potential in human clear cell renal cell carcinoma.
12/2012Antioxidant activity of vasoactive intestinal peptide in HK2 human renal cells.
10/2012Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation.
1/2012RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells.
1/2012Overexpression of vasoactive intestinal peptide receptors and cyclooxygenase-2 in human prostate cancer. Analysis of potential prognostic relevance.
12/2010Vasoactive intestinal peptide (VIP) induces malignant transformation of the human prostate epithelial cell line RWPE-1.
11/2010Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ana M Bajo Research Topics

Disease

21Neoplasms (Cancer)
01/2022 - 03/2002
21Prostatic Neoplasms (Prostate Cancer)
08/2020 - 02/2003
6Breast Neoplasms (Breast Cancer)
12/2016 - 09/2003
4Renal Cell Carcinoma (Grawitz Tumor)
08/2014 - 10/2012
3Carcinogenesis
01/2022 - 12/2010
3Carcinoma (Carcinomatosis)
01/2013 - 10/2002
2Wounds and Injuries (Trauma)
01/2018 - 05/2015
2Kidney Neoplasms (Kidney Cancer)
03/2016 - 12/2012
1Neoplastic Cell Transformation
01/2022
1Triple Negative Breast Neoplasms
12/2016
1Neoplasm Metastasis (Metastasis)
02/2013
1Hypoxia (Hypoxemia)
02/2013
1Kidney Diseases (Kidney Disease)
12/2012
1Disease Progression
10/2010
1Adenocarcinoma
06/2005
1Ovarian Neoplasms (Ovarian Cancer)
10/2002

Drug/Important Bio-Agent (IBA)

18Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))IBA
02/2015 - 06/2005
13AndrogensIBA
01/2020 - 02/2003
10Growth Hormone-Releasing Hormone (Somatotropin Releasing Hormone)IBA
01/2022 - 02/2003
10Messenger RNA (mRNA)IBA
10/2014 - 03/2002
10Proteins (Proteins, Gene)FDA Link
10/2014 - 03/2002
6Epidermal Growth Factor (EGF)IBA
12/2016 - 03/2002
6Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
02/2015 - 02/2003
5somatotropin releasing hormone receptorIBA
01/2018 - 02/2003
5Estrogens (Estrogen)FDA Link
12/2016 - 03/2002
5Peptides (Polypeptides)IBA
12/2012 - 03/2002
5Vasoactive Intestinal Peptide Receptors (Vasoactive Intestinal Peptide Receptor)IBA
01/2012 - 06/2005
4ErbB Receptors (EGF Receptor)IBA
12/2016 - 10/2002
3CytokinesIBA
01/2022 - 05/2009
3JV 1-38IBA
08/2016 - 02/2003
3Cyclooxygenase 2 (Cyclooxygenase-2)IBA
02/2015 - 05/2007
3Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
01/2012 - 11/2007
3Angiogenesis Inducing Agents (Angiogenesis Factor)IBA
01/2012 - 12/2007
3Biomarkers (Surrogate Marker)IBA
01/2012 - 05/2009
2RutheniumIBA
08/2020 - 05/2015
2Proliferating Cell Nuclear Antigen (PCNA)IBA
01/2017 - 08/2016
2Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
12/2016 - 12/2007
2PhAcTyr(1)- Arg(2)- P(H)e(4- CL)(6)- Ala(8)- Tyr(Me)(10)- His(11)- Abu(15)- His(20)- Nle(27)- Arg(28)- HLCr(29)- GHRH(1-29)NH2IBA
08/2016 - 02/2013
2Cyclin D1IBA
08/2016 - 05/2009
2Matrix Metalloproteinases (MMPs)IBA
02/2013 - 05/2009
2Metalloproteases (Metalloproteinases)IBA
02/2013 - 05/2009
2CateninsIBA
02/2013 - 01/2013
2Cadherins (E-Cadherin)IBA
02/2013 - 05/2009
2NeuropeptidesIBA
01/2013 - 12/2009
2Prostate-Specific Antigen (Semenogelase)IBA
01/2012 - 02/2003
2Gastrin-Releasing PeptideIBA
10/2010 - 03/2002
2BombesinIBA
10/2010 - 03/2002
2Tpi(6)-Leu(13)-psi(CH2NH)-Leu(14)- bombesin (6-14)IBA
10/2010 - 03/2002
2EnzymesIBA
12/2009 - 06/2005
2NF-kappa B (NF-kB)IBA
05/2009 - 05/2007
2AntibodiesIBA
04/2009 - 11/2007
2Tyrosine Kinase InhibitorsIBA
04/2009 - 11/2007
2Adenylyl Cyclases (Adenylyl Cyclase)IBA
12/2007 - 06/2005
2LHRH Receptors (Gonadotropin-Releasing Hormone Receptor)IBA
09/2003 - 10/2002
2Gonadotropin-Releasing Hormone (GnRH)FDA Link
09/2003 - 10/2002
1carbosilaneIBA
08/2020
1MetalsIBA
10/2019
1Cisplatin (Platino)FDA LinkGeneric
10/2019
1PalladiumIBA
10/2019
1Dendrimers (Dendrons)IBA
07/2019
1Har(29)- Arg(28) Nle(27) Orn(21) His(20) Orn(12,) Abu(15) His(11) Tyr(Me)(10) Har(9) Ala(8) Fpa(5,6) Arg(2) (PhAc-Ada)(0)-Tyr(1) GHRH(1-29)NH2IBA
01/2018
1MIA-690IBA
01/2018
1Bromodeoxyuridine (BrdU)IBA
01/2017
1CollagenIBA
01/2017
1Progesterone Receptors (Progesterone Receptor)IBA
12/2016
1Caspase 3 (Caspase-3)IBA
08/2016
1TitaniumIBA
03/2016
1Titanocene YIBA
03/2016
1Ruthenium CompoundsIBA
05/2015
1Antineoplastic Agents (Antineoplastics)IBA
05/2015
1Collagen Type I (Type I Collagen)IBA
05/2015
1erythromycin propionate-N-acetylcysteinateIBA
02/2015
1Small Interfering RNA (siRNA)IBA
01/2012
1Type I Vasoactive Intestinal Polypeptide ReceptorsIBA
01/2012
1Formaldehyde (Formol)FDA Link
01/2012
1ParaffinIBA
01/2012
1AN 215IBA
10/2010
1Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA
12/2009
1CurcuminIBA
12/2009
1N- (2- cyclohexyloxy- 4- nitrophenyl)methanesulfonamideIBA
12/2009
1Hemoglobins (Hemoglobin)IBA
09/2007
1matrigelIBA
09/2007
1lysine(6)-doxorubicin LHRHIBA
09/2003
1Doxorubicin (Adriamycin)FDA LinkGeneric
09/2003
1AN 204 (AN 201)IBA
10/2002
1AN 207IBA
10/2002
1Hca(6)-Leu(13)-psi(CH2N)-Tac(14)- bombesin(6-14)IBA
03/2002
1Oncogene Proteins (Oncogene Protein)IBA
03/2002

Therapy/Procedure

12Therapeutics
07/2019 - 03/2002
3Subcutaneous Injections
01/2022 - 09/2007
3Drug Therapy (Chemotherapy)
10/2010 - 10/2002
1Intravenous Administration
08/2020
1Injections
09/2003
1Castration
02/2003